We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MyMD Pharmaceuticals Inc. announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine storm, a major cause of severity and death in COVID-19 patients.
Akers Biosciences and MyMD Pharmaceuticals reported that a new study showed rising temperatures during spring and summer months are associated with slower rates of Covid-19 transmission, which is consistent with the seasonal respiratory virus’ behaviour.